Company profile
AREV Life Sciences Global Corp
OTC: AREVF · Healthcare · Medical - Pharmaceuticals
Canadian filerHQ Coquitlam, BCReports USD
#1091 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ —GM —SS 49
v0.1 · 5/100 weight · pillars only
↑ workforce scale, growth stability · ↓ return on assets, Altman-Z
Methodology →Revenue TTM
$5.3k
Rev growth YoY (TTM)
-96.3%
Net income (FY)
-$1.1M
Employees
19,534
as of 2026-08-29
Market cap
$15.9k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$37.7k49.1k CAD2022
Net income-$1.1M-1.4M CAD2022
Operating income-$1.1M-1.4M CAD2022
Total assets$186.5k252.6k CAD2022
Liabilities$889.9k1.2M CAD2022
Equity-$703.3k-952.6k CAD2022
Revenue trend
FY2017 – FY2022 · USD
FY17
FY18
FY19
FY20
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is AREV Life Sciences Global Corp’s revenue?
AREV Life Sciences Global Corp booked $37.7k in FY2022 revenue, contracting 81% year over year — slower than 88% of Healthcare companies we track, at a -2940.4% net margin.
Peers · Healthcare
Altimmune, Inc.55CNeonc Technologies Holdings, Inc.10DAXIM Biotechnologies, Inc.——Oragenics, Inc.46DHi-Great Group Holding Company25DGridAI Technologies Corp.30DKey facts
CEOMichael C. Withrow
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersCoquitlam, BC
ExchangeOTC: AREVF
Employees19,534
IPO date2019-04-30
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.